Emily Bodnar
Stock Analyst at H.C. Wainwright
(3.26)
# 2,463
Out of 5,043 analysts
699
Total ratings
37.4%
Success rate
2.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Emily Bodnar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARTV Artiva Biotherapeutics | Reiterated: Buy | $35 | $6.94 | +404.32% | 12 | Oct 1, 2026 | |
| RCUS Arcus Biosciences | Reiterated: Buy | $45 | $24.41 | +84.35% | 22 | Sep 25, 2026 | |
| AGEN Agenus | Reiterated: Buy | $25 | $7.67 | +225.95% | 42 | Sep 21, 2026 | |
| AUTL Autolus Therapeutics | Reiterated: Buy | $10 | $1.81 | +452.49% | 9 | Sep 21, 2026 | |
| GERN Geron | Reiterated: Hold | n/a | $1.23 | - | 15 | Sep 21, 2026 | |
| JSPR Jasper Therapeutics | Reiterated: Buy | $20 | $0.5702 | +3,407.54% | 23 | Sep 21, 2026 | |
| NKTX Nkarta | Reiterated: Buy | $14 | $2.25 | +522.22% | 32 | Sep 21, 2026 | |
| ODTX Odyssey Therapeutics | Reiterated: Buy | $44 | $19.00 | +131.58% | 3 | Sep 21, 2026 | |
| OLMA Olema Pharmaceuticals | Reiterated: Buy | $36 | $7.82 | +360.36% | 48 | Sep 21, 2026 | |
| PPBT Purple Biotech | Reiterated: Buy | $17 | $1.33 | +1,178.20% | 21 | Sep 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $2.79 | +150.90% | 28 | Sep 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $78 | $55.37 | +40.87% | 15 | Sep 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $42 | $31.18 | +34.70% | 12 | Sep 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $57 | $31.85 | +78.96% | 6 | Sep 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $31 | $2.56 | +1,110.94% | 16 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $1.08 | +2,214.81% | 27 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 | $10.72 | +226.49% | 27 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 | $1.91 | +894.76% | 25 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $7.18 | +178.55% | 16 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $52 → $60 | $31.62 | +89.75% | 4 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $0.3042 | +1,543.66% | 39 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $2.98 | +235.57% | 12 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $52 → $55 | $31.81 | +72.90% | 24 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $46 → $52 | $14.58 | +256.65% | 45 | Jul 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.44 | - | 27 | Jun 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $0.3144 | +3,716.79% | 5 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $55 → $66 | $45.95 | +43.63% | 20 | Mar 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $18 | $4.57 | +293.87% | 1 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $0.0002 | - | 24 | Nov 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $57.02 | $5.61 | +916.42% | 34 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $160 | $2.00 | n/a | 32 | Sep 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.86 | n/a | 22 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $0.87 | n/a | 5 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.8127 | n/a | 6 | May 22, 2024 |
Artiva Biotherapeutics
Oct 1, 2026
Reiterated: Buy
Price Target: $35
Current: $6.94
Upside: +404.32%
Arcus Biosciences
Sep 25, 2026
Reiterated: Buy
Price Target: $45
Current: $24.41
Upside: +84.35%
Agenus
Sep 21, 2026
Reiterated: Buy
Price Target: $25
Current: $7.67
Upside: +225.95%
Autolus Therapeutics
Sep 21, 2026
Reiterated: Buy
Price Target: $10
Current: $1.81
Upside: +452.49%
Geron
Sep 21, 2026
Reiterated: Hold
Price Target: n/a
Current: $1.23
Upside: -
Jasper Therapeutics
Sep 21, 2026
Reiterated: Buy
Price Target: $20
Current: $0.5702
Upside: +3,407.54%
Nkarta
Sep 21, 2026
Reiterated: Buy
Price Target: $14
Current: $2.25
Upside: +522.22%
Odyssey Therapeutics
Sep 21, 2026
Reiterated: Buy
Price Target: $44
Current: $19.00
Upside: +131.58%
Olema Pharmaceuticals
Sep 21, 2026
Reiterated: Buy
Price Target: $36
Current: $7.82
Upside: +360.36%
Purple Biotech
Sep 21, 2026
Reiterated: Buy
Price Target: $17
Current: $1.33
Upside: +1,178.20%
Sep 21, 2026
Reiterated: Buy
Price Target: $7
Current: $2.79
Upside: +150.90%
Sep 21, 2026
Reiterated: Buy
Price Target: $78
Current: $55.37
Upside: +40.87%
Sep 21, 2026
Reiterated: Buy
Price Target: $42
Current: $31.18
Upside: +34.70%
Sep 3, 2026
Reiterated: Buy
Price Target: $57
Current: $31.85
Upside: +78.96%
Aug 14, 2026
Reiterated: Buy
Price Target: $31
Current: $2.56
Upside: +1,110.94%
Aug 14, 2026
Reiterated: Buy
Price Target: $25
Current: $1.08
Upside: +2,214.81%
Aug 14, 2026
Reiterated: Buy
Price Target: $35
Current: $10.72
Upside: +226.49%
Aug 13, 2026
Reiterated: Buy
Price Target: $19
Current: $1.91
Upside: +894.76%
Aug 13, 2026
Reiterated: Buy
Price Target: $20
Current: $7.18
Upside: +178.55%
Aug 11, 2026
Rated: Buy
Price Target: $52 → $60
Current: $31.62
Upside: +89.75%
Aug 6, 2026
Reiterated: Buy
Price Target: $5
Current: $0.3042
Upside: +1,543.66%
Aug 6, 2026
Reiterated: Buy
Price Target: $10
Current: $2.98
Upside: +235.57%
Jul 30, 2026
Reiterated: Buy
Price Target: $52 → $55
Current: $31.81
Upside: +72.90%
Jul 24, 2026
Rated: Buy
Price Target: $46 → $52
Current: $14.58
Upside: +256.65%
Jun 15, 2026
Rated: Hold
Price Target: n/a
Current: $2.44
Upside: -
May 15, 2026
Reiterated: Buy
Price Target: $12
Current: $0.3144
Upside: +3,716.79%
Mar 30, 2026
Reiterated: Buy
Price Target: $55 → $66
Current: $45.95
Upside: +43.63%
Feb 23, 2026
Initiated Coverage: Buy
Price Target: $18
Current: $4.57
Upside: +293.87%
Nov 17, 2025
Reiterated: Hold
Price Target: n/a
Current: $0.0002
Upside: -
Oct 13, 2025
Reiterated: Buy
Price Target: $57.02
Current: $5.61
Upside: +916.42%
Sep 26, 2025
Reiterated: Buy
Price Target: $160
Current: $2.00
Upside: n/a
Apr 29, 2025
Rated: Hold
Price Target: n/a
Current: $1.86
Upside: n/a
Mar 31, 2025
Reiterated: Buy
Price Target: $8
Current: $0.87
Upside: n/a
May 22, 2024
Rated: Hold
Price Target: n/a
Current: $0.8127
Upside: n/a